nach oben

Journal of Endocrinological Investigation

02.05.2024 | Original Article

FBXO28 reduces high-fat diet-induced hyperlipidemia in mice by alleviating abnormal lipid metabolism and inflammatory responses

verfasst von: J. Sun, B. Du, M. Chen, J. Jia, X. Wang, J. Hong

Erschienen in: Journal of Endocrinological Investigation

Einloggen, um Zugang zu erhalten

Abstract

Background

Hyperlipidemia is a lipid metabolism disorder with increasing incidence and prevalence worldwide. Abnormal lipid metabolism and inflammation are two significant characteristics of hyperlipidemia. The purpose of this study was to explore the role and mechanism of F-box only protein 28 (FBXO28) in hyperlipidemia.

Methods

Mice were fed with high-fat diet (HFD) to elicit obesity, and 3T3-L1 preadipocytes were stimulated with MDI cocktail (IBMX, DEX and insulin) to evoke differentiation. In vivo and in vitro role of FBXO28 in hyperlipidemia was investigated by hematoxylin–eosin and oil Red O staining, the lipid biochemistry measurement, enzyme-linked immunosorbent assay, reverse transcription quantitative polymerase chain reaction and western blotting assays. The mechanism of FBXO28 explored by co-immunoprecipitation, immunofluorescence, ubiquitination and cycloheximide assays.

Results

Low expression of FBXO28 was found in hyperlipidemia in silico, in vivo and in vitro. Upregulation of FBXO28 declined the body weight, fat accumulation, and serum lipid content in HFD-fed mice. Abnormal lipid accumulation, and the level of liposynthetic genes and beta-oxidation related genes were improved by overexpression of FBXO28 both in HFD-elicited mice and MDI-treated 3T3-L1 preadipocytes. Besides, overexpression of FBXO28 declined HFD-induced the level of proinflammatory factors and F4/80. Mechanically, FBXO28 directly bound RAB27A and promoted its ubiquitinated degradation. Thus, upregulation of RAB27A inverted the improved role of FBXO28 in abnormal lipid metabolism and inflammation in vivo and in vitro.

Conclusion

FBXO28 ameliorated abnormal lipid metabolism and inflammation through the ubiquitinated degradation of RAB27A, thereby attenuating HFD-induced hyperlipidemia. The results could promote the treatment of hyperlipidemia, and the relevant diseases.

Nur mit Berechtigung zugänglich

Karr S (2017) Epidemiology and management of hyperlipidemia. Am J Manag Care 23(9 Suppl):S139–S148PubMed

Stewart J, McCallin T, Martinez J, Chacko S, Yusuf S (2020) Hyperlipidemia. Pediatr Rev 41(8):393–402PubMedCrossRef

Bozzetto L, Della Pepa G, Vetrani C, Rivellese AA (2020) Dietary Impact on postprandial lipemia. Front Endocrinol (Lausanne) 11:337PubMedCrossRef

Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M et al (2016) Heart disease and stroke statistics-2016 update: a report from the American heart association. Circulation 133(4):e38-360PubMed

Bjornstad P, Eckel RH (2018) Pathogenesis of lipid disorders in insulin resistance: a brief review. Curr Diab Rep 18(12):127PubMedPubMedCentralCrossRef

Kopin L, Lowenstein C (2010) In the clinic. dyslipidemia. Ann Intern Med. https://doi.org/10.7326/0003-4819-153-3-201008030-01002CrossRefPubMed

Ye X, Kong W, Zafar MI, Chen LL (2019) Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. Cardiovasc Diabetol 18(1):48PubMedPubMedCentralCrossRef

Vekic J, Zeljkovic A, Stefanovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V (2019) Obesity and dyslipidemia. Metabolism 92:71–81PubMedCrossRef

Zheng D, Dou J, Liu G, Pan Y, Yan Y, Liu F et al (2019) Association between triglyceride level and glycemic control among insulin-treated patients with type 2 diabetes. J Clin Endocrinol Metab 104(4):1211–1220PubMedCrossRef

10.

Tang Q, Gao L, Tong Z, Li W (2022) Hyperlipidemia, COVID-19 and acute pancreatitis: a tale of three entities. Am J Med Sci 364(3):257–263PubMedPubMedCentralCrossRef

11.

Johnson CB, Davis MK, Law A, Sulpher J (2016) Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients. Can J Cardiol 32(7):900–907PubMedCrossRef

12.

Séguro F, Bongard V, Bérard E, Taraszkiewicz D, Ruidavets JB, Ferrières J (2015) Dutch lipid clinic network low-density lipoprotein cholesterol criteria are associated with long-term mortality in the general population. Arch Cardiovasc Dis 108(10):511–518PubMedCrossRef

13.

Ferrières J (2019) Hypercholesterolaemia and coronary artery disease: A silent killer with several faces. Arch Cardiovasc Dis 112(2):75–78PubMedCrossRef

14.

Law MR, Wald NJ, Thompson SG (1994) By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 308(6925):367–372PubMedPubMedCentralCrossRef

15.

Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG (1973) Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52(7):1544–1568. https://doi.org/10.1172/JCI107332CrossRefPubMedPubMedCentral

16.

Tietge UJ (2014) Hyperlipidemia and cardiovascular disease: inflammation, dyslipidemia, and atherosclerosis. Curr Opin Lipidol 25(1):94–95PubMedCrossRef

17.

Clarke MC, Talib S, Figg NL, Bennett MR (2010) Vascular smooth muscle cell apoptosis induces interleukin-1-directed inflammation: effects of hyperlipidemia-mediated inhibition of phagocytosis. Circ Res 106(2):363–372PubMedCrossRef

18.

Madjid M, Willerson JT (2011) Inflammatory markers in coronary heart disease. Br Med Bull 100:23–38PubMedCrossRef

19.

Kratz AS, Richter KT, Schlosser YT, Schmitt M, Shumilov A, Delecluse HJ et al (2016) Fbxo28 promotes mitotic progression and regulates topoisomerase IIα-dependent DNA decatenation. Cell Cycle 15(24):3419–3431PubMedPubMedCentralCrossRef

20.

Cepeda D, Ng HF, Sharifi HR, Mahmoudi S, Cerrato VS, Fredlund E et al (2013) CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Mol Med 5(7):1067–1086PubMedCrossRef

21.

Cassina M, Rigon C, Casarin A, Vicenzi V, Salviati L, Clementi M (2015) FBXO28 is a critical gene of the 1q41q42 microdeletion syndrome. Am J Med Genet A 167(6):1418–1420PubMedCrossRef

22.

Papetti L, Schettini L, Garone G, Gennaro E, Malacarne M, Properzi E et al (2016) The crucial role of FBXO28 in the pathogenesis of the 1q41q42 microdeletion syndrome. Am J Med Genet A 170(11):3041–3042PubMedCrossRef

23.

Au PY, Argiropoulos B, Parboosingh JS, Micheil IA (2014) Refinement of the critical region of 1q41q42 microdeletion syndrome identifies FBXO28 as a candidate causative gene for intellectual disability and seizures. Am J Med Genet A 164(2):441–448. https://doi.org/10.1002/ajmg.a.36320CrossRef

24.

Schneider AL, Myers CT, Muir AM, Calvert S, Basinger A, Perry MS et al (2021) FBXO28 causes developmental and epileptic encephalopathy with profound intellectual disability. Epilepsia 62(1):e13–e21PubMedCrossRef

25.

Zou JF, Wu XN, Shi RH, Sun YQ, Qin FJ, Yang YM (2020) Inhibition of microRNA-184 reduces H2O2-mediated cardiomyocyte injury via targeting FBXO28. Eur Rev Med Pharmacol Sci 24(21):11251–11258PubMed

26.

Gorrepati KDD, He W, Lupse B, Yuan T, Maedler K, Ardestani A (2018) An SCFFBXO28 E3 Ligase Protects Pancreatic β-Cells from Apoptosis. Int J Mol Sci. https://doi.org/10.3390/ijms19040975CrossRefPubMedPubMedCentral

27.

Liu S, Liu P, Zhu C, Yang R, He Z, Li Y et al (2023) FBXO28 promotes proliferation, invasion, and metastasis of pancreatic cancer cells through regulation of SMARCC2 ubiquitination. Aging (Albany NY) 15(12):5381–5398PubMed

28.

Phillips E, Balss J, Bethke F, Pusch S, Christen S, Hielscher T et al (2022) PFKFB4 interacts with FBXO28 to promote HIF-1α signaling in glioblastoma. Oncogenesis 11(1):57PubMedPubMedCentralCrossRef

29.

Zhang Y, Liu Q, Cui M, Wang M, Hua S, Gao J et al (2021) Comprehensive analysis of expression, prognostic value, and Immune infiltration for ubiquitination-related FBXOS in pancreatic ductal adenocarcinoma. Front Immunol 12:774435PubMedCrossRef

30.

Liu Y, Pan B, Qu W, Cao Y, Li J, Zhao H (2021) Systematic analysis of the expression and prognosis relevance of FBXO family reveals the significance of FBXO1 in human breast cancer. Cancer Cell Int 21(1):130PubMedPubMedCentralCrossRef

31.

Yu T, Wang L, Zhao C, Qian B, Yao C, He F et al (2019) Sublytic C5b–9 induces proliferation of glomerular mesangial cells via ERK5/MZF1/RGC-32 axis activated by FBXO28-TRAF6 complex. J Cell Mol Med 23(8):5654–5671PubMedPubMedCentralCrossRef

32.

Boucher JM, Robich M, Scott SS, Yang X, Ryzhova L, Turner JE et al (2018) Rab27a regulates human perivascular adipose progenitor cell differentiation. Cardiovasc Drugs Ther 32(5):519–530PubMedPubMedCentralCrossRef

33.

Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. https://doi.org/10.2202/1544-6115.1027CrossRefPubMed

34.

National Research Council Committee for the Update of the Guide for the C, Use of Laboratory A. 2011 The National Academies Collection: Reports funded by National Institutes of Health. Guide for the Care and Use of Laboratory Animals. Washington (DC): National Academies Press (US) Copyright © 2011, National Academy of Sciences.

35.

Liang Z, Zhang X, Liu Y, Wu Q, You C (2021) SEMA3A protects against hyperoxia-induced lung injury in a bronchopulmonary dysplasia model of newborn rat by inhibiting ERK pathway. Allergol Immunopathol (Madr) 49(6):8–15PubMedCrossRef

36.

Kang YM, Kang HA, Cominguez DC, Kim SH, An HJ (2021) Papain Ameliorates lipid accumulation and inflammation in high-fat diet-induced obesity mice and 3T3-L1 adipocytes via AMPK activation. Int J Mol Sci. https://doi.org/10.3390/ijms22189885CrossRefPubMedPubMedCentral

37.

Liu L, Ji X, Huang X (2022) Dexmedetomidine improves myocardial ischemia-reperfusion injury by increasing autophagy via PINK1/PRKN pathway. Signa Vitae 18(5):125–132

38.

Manríquez-Olmos L, Garrocho-Rangel A, Pozos-Guillén A, Ortiz-Magdaleno M, Escobar-García DM (2022) Effect of tricalcium silicate cements in gene expression of COL1A1, MAPK’s, and NF-kB, and cell adhesion in primary teeth’ pulp fibroblasts. J Clin Pediatr Dent 46(6):17–24PubMedCrossRef

39.

Lee EH, Lee JN, Park S, Chun SY, Yoon BH, Chung J-W et al (2022) Inhibition of TRPM7 suppresses migration and invasion of prostate cancer cells via inactivation of ERK1/2, Src and Akt pathway signaling. J Men’s Health 18(7):1–10CrossRef

40.

Gomez MK, Thomson JP, Grimes GR, Wang AT, Churchman M, O’Connor MJ et al (2022) Identifying and overcoming a mechanism of resistance to WEE1 kinase inhibitor AZD1775 in high grade serous ovarian cancer cells. Eur J Gynaecol Oncol 43(2):183–195CrossRef

41.

Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE et al (2009) Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 69(23):9065–9072PubMedCrossRef

42.

Taghizadeh E, Esfehani RJ, Sahebkar A, Parizadeh SM, Rostami D, Mirinezhad M et al (2019) Familial combined hyperlipidemia: an overview of the underlying molecular mechanisms and therapeutic strategies. IUBMB Life 71(9):1221–1229PubMedCrossRef

43.

Guo L, Kang JS, Park YH, Je BI, Lee YJ, Kang NJ et al (2020) S-petasin inhibits lipid accumulation in oleic acid-induced HepG2 cells through activation of the AMPK signaling pathway. Food Funct 11(6):5664–5673PubMedCrossRef

44.

Gluchowski NL, Becuwe M, Walther TC, Farese RV Jr (2017) Lipid droplets and liver disease: from basic biology to clinical implications. Nat Rev Gastroenterol Hepatol 14(6):343–355PubMedPubMedCentralCrossRef

45.

Lee HJ, Le B, Lee DR, Choi BK, Yang SH (2018) Cissus quadrangularis extract (CQR-300) inhibits lipid accumulation by downregulating adipogenesis and lipogenesis in 3T3-L1 cells. Toxicol Rep 5:608–614PubMedPubMedCentralCrossRef

46.

Qi G, Guo R, Tian H, Li L, Liu H, Mi Y et al (2018) Nobiletin protects against insulin resistance and disorders of lipid metabolism by reprogramming of circadian clock in hepatocytes. Biochim Biophys Acta Mol Cell Biol Lipids 1863(6):549–562PubMedCrossRef

47.

Bitter A, Nüssler AK, Thasler WE, Klein K, Zanger UM, Schwab M et al (2015) Human sterol regulatory element-binding protein 1a contributes significantly to hepatic lipogenic gene expression. Cell Physiol Biochem 35(2):803–815PubMedCrossRef

48.

Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S (2011) The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. J Adv Pharm Technol Res 2(4):236–240PubMedPubMedCentralCrossRef

49.

Liss KH, Finck BN (2017) PPARs and nonalcoholic fatty liver disease. Biochimie 136:65–74PubMedCrossRef

50.

Dreyer C, Keller H, Mahfoudi A, Laudet V, Krey G, Wahli W (1993) Positive regulation of the peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR). Biol Cell 77(1):67–76PubMedCrossRef

51.

Gervois P, Torra IP, Fruchart JC, Staels B (2000) Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med 38(1):3–11PubMedCrossRef

52.

Pawlak M, Lefebvre P, Staels B (2015) Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol 62(3):720–733PubMedCrossRef

53.

Cui S, Pan XJ, Ge CL, Guo YT, Zhang PF, Yan TT et al (2021) Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α. Chin J Nat Med 19(6):401–411PubMed

54.

Duan J, Wang Z, Duan R, Yang C, Zhao R, Feng Q et al (2022) Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice. Hepatology 75(1):140–153PubMedCrossRef

55.

Vega RB, Huss JM, Kelly DP (2000) The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 20(5):1868–1876PubMedPubMedCentralCrossRef

56.

Cheng CF, Ku HC, Lin H. PGC-1α as a Pivotal Factor in Lipid and Metabolic Regulation. Int J Mol Sci. 2018;19(11).

57.

Kelly DP, Scarpulla RC (2004) Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev 18(4):357–368PubMedCrossRef

58.

Kim Y, Lim JH, Kim EN, Hong YA, Park HJ, Chung S et al (2022) Adiponectin receptor agonist ameliorates cardiac lipotoxicity via enhancing ceramide metabolism in type 2 diabetic mice. Cell Death Dis 13(3):282PubMedPubMedCentralCrossRef

59.

Kojta I, Chacińska M, Błachnio-Zabielska A (2020) Obesity, bioactive lipids, and adipose tissue inflammation in insulin resistance. Nutrients. https://doi.org/10.3390/nu12051305CrossRefPubMedPubMedCentral

60.

Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A et al (2003) Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 285(3):E527–E533PubMedCrossRef

61.

Shimada-Sugawara M, Sakai E, Okamoto K, Fukuda M, Izumi T, Yoshida N et al (2015) Rab27A regulates transport of cell surface receptors modulating multinucleation and lysosome-related organelles in osteoclasts. Sci Rep 5:9620PubMedPubMedCentralCrossRef

62.

Li X, Wang H, Ni Q, Tang Z, Ni J, Xu L et al (2017) Effects of silencing Rab27a gene on biological characteristics and chemosensitivity of non-small cell lung cancer. Oncotarget 8(55):94481–94492PubMedPubMedCentralCrossRef

63.

Li J, Jin Q, Huang F, Tang Z, Huang J (2017) Effects of Rab27A and Rab27B on invasion, proliferation, apoptosis, and chemoresistance in human pancreatic cancer cells. Pancreas 46(9):1173–1179PubMedCrossRef

64.

Dong W, Cui J, Yang J, Li W, Wang S, Wang X et al (2015) Decreased expression of Rab27A and Rab27B correlates with metastasis and poor prognosis in colorectal cancer. Discov Med 20(112):357–367PubMed

65.

Zhang X, Zhang Y, Yang J, Li S, Chen J (2015) Upregulation of miR-582-5p inhibits cell proliferation, cell cycle progression and invasion by targeting Rab27a in human colorectal carcinoma. Cancer Gene Ther 22(10):475–480PubMedCrossRef

66.

Smith VL, Cheng Y, Bryant BR, Schorey JS (2017) Exosomes function in antigen presentation during an in vivo mycobacterium tuberculosis infection. Sci Rep 7:43578PubMedPubMedCentralCrossRef

67.

Luo Y, Yu MH, Yan YR, Zhou Y, Qin SL, Huang YZ et al (2020) Rab27A promotes cellular apoptosis and ROS production by regulating the miRNA-124-3p/STAT3/RelA signalling pathway in ulcerative colitis. J Cell Mol Med 24(19):11330–11342PubMedPubMedCentralCrossRef

Titel: FBXO28 reduces high-fat diet-induced hyperlipidemia in mice by alleviating abnormal lipid metabolism and inflammatory responses
verfasst von: J. Sun
B. Du
M. Chen
J. Jia
X. Wang
J. Hong
Publikationsdatum: 02.05.2024
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-024-02376-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen